Staphylococcus aureus antigen-containing whole cell vaccine
AssigneeNabi
InventorAli Ibrahim Fattom
Life of this patent
Estimating the term…
Abstract
A negatively-charged S. aureus antigen contains β-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing S. aureus infection. A whole cell vaccine of cells that contain the antigen is particularly useful in the treatment of mastitis.
Claims4
An immunotherapy method comprising administering to a subject an immunostimulatory amount of a composition that comprises (A) cells, cell lysates, or cell derivatives of Staphylococcus aureus which carry an antigen that (i) comprises β-linked hexosamine, (ii) contains no O-acetyl groups detectable by nuclear magnetic resonance spectroscopy, and (iii) specifically bind with antibodies to Staphylococcus aureus Type 336 deposited under ATCC 55804, and (B) a pharmaceutically acceptable carrier.
An immunotherapy method comprising administering to a subject an immunostimulatory amount of a composition prepared by a process comprising
- selecting cells of Staphylococcus aureus which carry an antigen that (i) comprises β-linked hexosamine, (ii) contains no O-acetyl groups detectable by nuclear magnetic resonance spectroscopy, and (iii) specifically binds with antibodies to Staphylococcus aureus Type 336 deposited under ATCC 55804,
- inactivating said cells, and
- mixing said cells, or lysates or derivatives of said cells, with a pharmaceutically acceptable carrier.
A method of preparing a whole cell vaccine, comprising
- selecting cells of Staphylococcus aureus which carry an antigen that (i) comprises β-linked hexosamine, (ii) contains no O-acetyl groups detectable by nuclear magnetic resonance spectroscopy, and (iii) specifically binds with antibodies to Staphylococcus aureus Type 336 deposited under ATCC 55804, or lysates or derivatives of said cells,
- inactivating said cells, and
- mixing said cells, or lysates or derivatives of said cells, with a pharmaceutically acceptable carrier,
- wherein said cells are selected using antibodies to said antigen.
Dependencies are inferred from the claim text.